Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study

被引:58
|
作者
Ehmann, Lisa [1 ,2 ]
Zoller, Michael [3 ]
Minichmayr, Iris K. [1 ,2 ]
Scharf, Christina [3 ]
Maier, Barbara [4 ]
Schmitt, Maximilian V. [5 ]
Hartung, Niklas [1 ,6 ]
Huisinga, Wilhelm [6 ]
Vogeser, Michael [4 ]
Frey, Lorenz [3 ]
Zander, Johannes [4 ]
Kloft, Charlotte [1 ]
机构
[1] Free Univ Berlin, Inst Pharm, Dept Clin Pharm & Biochem, Kelchstr 31, D-12169 Berlin, Germany
[2] PharMetrX, Grad Res Training Program, Berlin, Germany
[3] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Anesthesiol, Munich, Germany
[4] Ludwig Maximilians Univ Munchen, Univ Hosp, Inst Lab Med, Munich, Germany
[5] Heidelberg Univ, Inst Pharm & Mol Biotechnol, Heidelberg, Germany
[6] Univ Potsdam, Inst Math, Potsdam, Germany
来源
CRITICAL CARE | 2017年 / 21卷
关键词
beta-Lactam; Intensive care; Pharmacokinetics/Pharmacodynamics; Target attainment; Renal function; Risk assessment tool; Continuous renal replacement therapy; RANDOMIZED CONTROLLED-TRIAL; POPULATION PHARMACOKINETICS; SEVERE SEPSIS; CONTINUOUS-INFUSION; REPLACEMENT THERAPY; INTERMITTENT BOLUS; SEPTIC SHOCK; MULTICENTER; PHARMACODYNAMICS; REQUIREMENTS;
D O I
10.1186/s13054-017-1829-4
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Severe bacterial infections remain a major challenge in intensive care units because of their high prevalence and mortality. Adequate antibiotic exposure has been associated with clinical success in critically ill patients. The objective of this study was to investigate the target attainment of standard meropenem dosing in a heterogeneous critically ill population, to quantify the impact of the full renal function spectrum on meropenem exposure and target attainment, and ultimately to translate the findings into a tool for practical application. Methods: A prospective observational single-centre study was performed with critically ill patients with severe infections receiving standard dosing of meropenem. Serial blood samples were drawn over 4 study days to determine meropenem serum concentrations. Renal function was assessed by creatinine clearance according to the Cockcroft and Gault equation (CLCRCG). Variability in meropenem serum concentrations was quantified at the middle and end of each monitored dosing interval. The attainment of two pharmacokinetic/pharmacodynamic targets (100% T->MIC, 50% T->4xMIC) was evaluated for minimum inhibitory concentration (MIC) values of 2 mg/L and 8 mg/L and standard meropenem dosing (1000 mg, 30-minute infusion, every 8 h). Furthermore, we assessed the impact of CLCRCG on meropenem concentrations and target attainment and developed a tool for risk assessment of target non-attainment. Results: Large inter-and intra-patient variability in meropenem concentrations was observed in the critically ill population (n = 48). Attainment of the target 100% T->MIC was merely 48.4% and 20.6%, given MIC values of 2 mg/L and 8 mg/L, respectively, and similar for the target 50% T->4xMIC. A hyperbolic relationship between CLCRCG (25-255 ml/minute) and meropenem serum concentrations at the end of the dosing interval (C-8h) was derived. For infections with pathogens of MIC 2 mg/L, mild renal impairment up to augmented renal function was identified as a risk factor for target non-attainment (for MIC 8 mg/L, additionally, moderate renal impairment). Conclusions: The investigated standard meropenem dosing regimen appeared to result in insufficient meropenem exposure in a considerable fraction of critically ill patients. An easy-and free-to-use tool (the MeroRisk Calculator) for assessing the risk of target non-attainment for a given renal function and MIC value was developed.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients
    Iris K. Minichmayr
    André Schaeftlein
    Joseph L. Kuti
    Markus Zeitlinger
    Charlotte Kloft
    Clinical Pharmacokinetics, 2017, 56 : 617 - 633
  • [22] Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases
    Isla, A.
    Canut, A.
    Arribas, J.
    Asin-Prieto, E.
    Rodriguez-Gascon, A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2016, 35 (03) : 511 - 519
  • [23] Early Target Attainment With Continuous Infusion Meropenem and Piperacillin/Tazobactam and Utilization of Therapeutic Drug Monitoring in Critically Ill Patients: A Retrospective Cohort Study From 2017 to 2020
    Drager, Sarah
    von Rotz, Matthias
    Labhardt, Niklaus D.
    Siegemund, Martin
    Rentsch, Katharina M.
    Osthoff, Michael
    Franzeck, Fabian C.
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (04):
  • [24] Beta-lactam antibiotic concentrations in critically ill patients with standard and adjusted dosages: A prospective observational study
    Areskog Lejbman, Ilja
    Torisson, Gustav
    Resman, Fredrik
    Sjovall, Fredrik
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2024, 68 (04) : 530 - 537
  • [25] Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients
    Minichmayr, Iris K.
    Schaeftlein, Andre
    Kuti, Joseph L.
    Zeitlinger, Markus
    Kloft, Charlotte
    CLINICAL PHARMACOKINETICS, 2017, 56 (06) : 617 - 633
  • [26] A prospective, observational study comparing the PK/PD relationships of generic Meropenem (Mercide (R)) to the innovator brand in critically ill patients
    Mer, Mervyn
    Snyman, Jacques Rene
    van Rensburg, Constance Elizabeth Jansen
    van Tonder, Jacob John
    Laurens, Ilze
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2016, 8 : 191 - 198
  • [27] Pathogen-based target attainment of optimized continuous infusion dosing regimens of piperacillin-tazobactam and meropenem in surgical ICU patients: a prospective single center observational study
    De Corte, Thomas
    Verhaeghe, Jarne
    Dhaese, Sofie
    Van Vooren, Sarah
    Boelens, Jerina
    G. Verstraete, Alain
    Stove, Veronique
    Ongenae, Femke
    De Bus, Liesbet
    Depuydt, Pieter
    Van Hoecke, Sofie
    J. De Waele, Jan
    ANNALS OF INTENSIVE CARE, 2023, 13 (01)
  • [28] Pathogen-based target attainment of optimized continuous infusion dosing regimens of piperacillin-tazobactam and meropenem in surgical ICU patients: a prospective single center observational study
    Thomas De Corte
    Jarne Verhaeghe
    Sofie Dhaese
    Sarah Van Vooren
    Jerina Boelens
    Alain G. Verstraete
    Veronique Stove
    Femke Ongenae
    Liesbet De Bus
    Pieter Depuydt
    Sofie Van Hoecke
    Jan J. De Waele
    Annals of Intensive Care, 13
  • [29] Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
    Mieke Carlier
    Sofie Carrette
    Jason A Roberts
    Veronique Stove
    Alain Verstraete
    Eric Hoste
    Pieter Depuydt
    Johan Decruyenaere
    Jeffrey Lipman
    Steven C Wallis
    Jan J De Waele
    Critical Care, 17
  • [30] Trough concentrations of meropenem and piperacillin during slow extended dialysis in critically ill patients with intermittent and continuous infusion: A prospective observational study
    Liebchen, Uwe
    Paal, Michael
    Bucher, Veronika
    Vogeser, Michael
    Irlbeck, Michael
    Schroeder, Ines
    Zoller, Michael
    Scharf, Christina
    JOURNAL OF CRITICAL CARE, 2022, 67 : 26 - 32